This plain language summary describes the results of a Phase 3 study called KarMMa-3. In this ongoing study, researchers looked at a relatively new treatment for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed)This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises the results of a Phase 3 ongoing study called KarMMa-3. Researchers looked at the safety and effectiveness of a novel treatment called ide-cel (compared to a standard of care regimen) for people with multiple myeloma, a type of blood cancer, whose cancer got worse despite treatment (refractory) or had cancer that at first improved with treatment, but eventually stopped responding (relapsed).

Visit the site using the link to read the article.

This PLSP is based on an article called ‘Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma’ and was published in The New England Journal of Medicine. 

Visit the New England Journal of Medicine site using the link to read the article.